Given the established beneficial effects on ASCVD risk reduction, GLP-1 RAs should be considered as the preferred agent for decreasing ASCVD risk in patients with T2DM and overweight/obesity. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.